#### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 4 July 01, 2014

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL OMB** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

subject to Section 16. Form 4 or

Check this box

if no longer

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

Common

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person * CULPEPPER PETER R			2. Issuer Name and Ticker or Trading Symbol PROVECTUS BIOPHARMACEUTICALS, INC. [PVCT]					5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  Director 10% Owner			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)				_X_ Officer (give below)	titleOthe	below)		
7327 OAK	(Month 7327 OAK RIDGE HWY., SUITE A 06/28/			•				CFO & COO			
(Street) 4. If Ame			ndment, Da	te Original			6. Individual or Joint/Group Filing(Check				
KNOXVILLE, TN 37931				nth/Day/Year	,			Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		n Date, if	3. Transaction Code (Instr. 8)	4. Securitie or(A) or Disp (Instr. 3, 4 a	osed c		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	06/28/2014			M	100,000	A	\$ 1.25	1,112,332	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

121,000

Ι

401(k)

plan

#### Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	FransactiorDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
(21150110)	Derivative Security		(110.11.11.21.1)	(1113111 0)	Disp	osed of (D) : 3, 4, and				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Stock Option (right to buy)	\$ 1.25	06/28/2014		M		100,000	06/28/2004	06/28/2014	Common Stock	100,000

## **Reporting Owners**

	Relationships
Reporting Owner Name / Address	•

Director 10% Owner Officer Other

CULPEPPER PETER R 7327 OAK RIDGE HWY. SUITE A

CFO & COO

KNOXVILLE, TN 37931

### **Signatures**

/s/ Peter R. 07/01/2014 Culpepper

\*\*Signature of Date Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2